Rhythm Pharmaceuticals, Inc.
RYTM
Positions held
Your positionsRYTM isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Rhythm Pharmaceuticals operates in the growing biotechnology sector, focusing on innovative treatments for rare diseases, which positions it well for potential breakthroughs and market expansion.
- In Q2 2026, Rhythm reported a revenue increase of 19% compared to the previous quarter, reaching $71 million.
- The company's gross margin remains strong at 87.5%, indicating efficient production and pricing strategies.
- The company's financial health is concerning, with a negative profit margin of -85.59% and a significant operating margin of -68.14% in the latest quarter.
- Rhythm's debt-to-equity ratio stands at 50.52, suggesting high leverage and potential financial risk.
- The stock has a 'Strong Sell' signal with a score of -16.00, indicating bearish market sentiment and technical weaknesses.
Fundamentals
| Market cap | $6.17B | Enterprise value | $6.07B | Trailing P/E | — | Forward P/E | -169.63 |
| PEG | — | Price / book | 59.92 | Beta | 2.01 | Dividend yield | 0.00% |
| Revenue growth | 46.9% | Earnings growth | — | Gross margin | 89.0% | Operating margin | -68.1% |
| Profit margin | -85.6% | ROE | -117.0% | ROA | -31.0% | Debt / equity | 0.51 |
| Current ratio | 3.45 | Free cash flow | -$130.59M | Analyst recommendation | none | Mean target | $138.82 |
| 52w high | $122.20 | 52w low | $74.50 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $71.3M | $60.1M | $57.3M | $51.3M | $48.5M |
| Op margin | -68.1% | -87.1% | -82.2% | -102.6% | -93.4% |
| Net income | -$49.3M | -$55.6M | -$47.5M | -$52.9M | -$46.6M |
| Gross margin | 87.5% | 88.1% | 91.6% | 89.3% | 88.6% |
| Gross profit | $62.3M | $53.0M | $52.5M | $45.8M | $43.0M |
| Operating income | -$48.6M | -$52.4M | -$47.1M | -$52.7M | -$45.3M |
- Revenue +19% vs prior quarter ($71M vs $60M).
- Gross margin 87.5% (was 88.1% prior quarter).
- Operating margin expanded to -68.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $190M | $130M | $77.4M | $23.6M |
| Op margin | -101.2% | -204.0% | -238.1% | -757.9% |
| Net income | -$197M | -$261M | -$185M | -$181M |
| Gross margin | 89.7% | 89.7% | 88.0% | 91.0% |
| Gross profit | $170M | $117M | $68.1M | $21.5M |
| Operating income | -$192M | -$266M | -$184M | -$179M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Rhythm's Imcivree Launch in Hypothalamic Obesity Encouraging, RBC Says
2026-10-08 · RBC Lifts Price Target on Rhythm Pharmaceuticals to $159 From $155, Keeps Outperform, Speculative Risk
2026-09-22 · Rhythm Pharmaceuticals Gains Health Canada Approval for Imcivree
2026-09-18 · Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?
2026-09-17 · Wolfe Research Initiates Rhythm Pharmaceuticals at Outperform
2026-09-15 · Rhythm Pharmaceuticals Insider Sold Shares Worth $5,133,442, According to a Recent SEC Filing
2026-09-11 · Billionaire Stanley Druckenmiller’s 2 New Healthcare Stock Picks
2026-09-10 · Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
2026-09-03 · An AI drug specialist zeroes in on rare forms of obesity
2026-08-28 · Moderna upgraded, Allstate downgraded: Wall Street's top analyst calls
Price (daily)
Full chart · RSI · MACD · patterns